摘要
目的 探讨甲磺酸阿帕替尼联合活血利水方治疗恶性腹腔积液的临床效果和安全性。方法 回顾性选取40例恶性腹腔积液患者,根据随机数字表法分为试验组(20例)与对照组(20例)。对照组予以支持治疗及甲磺酸阿帕替尼片治疗,试验组在对照组的基础上予以活血利水方“调营饮”治疗。比较两组近期客观疗效,中医证候疗效,治疗前后的中医证候积分、B超探查腹水深度及生活质量评分,不良反应发生情况。结果 与对照组70.00%相比,试验组近期客观疗效95.00%较高(P<0.05)。与对照组60.00%相比,试验组中医证候疗效90.00%较高(P<0.05)。与治疗前相比,两组治疗后中医证候积分、B超探查腹水深度、症状领域生活质量评分降低,功能领域、总体健康状况生活质量评分升高(P<0.05);且治疗后,试验组中医证候积分(11.45±2.61)分、B超探查腹水深度(42.63±11.41)mm、症状领域生活质量评分(20.26±15.48)分低于对照组的(13.22±2.77)分、(51.28±14.66)mm、(31.48±16.42)分,功能领域生活质量评分(61.55±9.09)分、总体健康状况生活质量评分(36.57±11.28)分高于对照组的(55.33±8.90)、(29.55±10.13)分(P<0.05)。两组不良反应发生率比较相比无差异(P>0.05)。结论 甲磺酸阿帕替尼联合活血利水方治疗恶性腹腔积液的疗效显著,是一种安全且有效、不良反应少、患者接受度好的有效方案。
Objective To explore the clinical effect and safety of apatinib mesylate combined with Huoxue Lishui prescript in the treatment of malignant ascites.Methods A retrospective analysis was performed on 40 patients with malignant ascites.They were divided into an experimental group(20 cases)and a control group(20 cases)according to random numerical table.The control group was given support treatment and apatinib mesylate tablet,and the experimental group was given Huoxue Lishui prescript"Tiaoyingyin"orally on the basis of the control group.Comparison was made on short-term objective efficacy,traditional Chinese medicine syndrome efficacy,traditional Chinese medicine syndrome score,depth of ascites detected by B-ultrasound and quality of life score before and after treatment,and the occurrence of adverse reactions between the two groups.Results Compared with the control group(70.00%),the short-term objective efficacy of the experimental group(95.00%)was higher(P<0.05).Compared with the control group(60.00%),the therapeutic effect of traditional Chinese medicine syndrome in the experimental group(90.00%)was higher(P<0.05).Compared with before treatment,traditional Chinese medicine syndrome score,depth of ascites detected by B-ultrasound and score of quality of life in symptom domain decreased,while the score of quality of life in functional domain and overall health status increased in both groups after treatment(P<0.05).After treatment,the traditional Chinese medicine syndrome score of the experimental group was(11.45±2.61)points,the depth of ascites detected by B-ultrasound was(42.63±11.41)mm,and the score of quality of life in symptom domain was(20.26±15.48)points,which was lower than(13.22±2.77),(51.28±14.66)mm,and(31.48±16.42)points in the control group;the scores of quality of life in functional domain and overall health status in the experimental group were(61.55±9.09)and(36.57±11.28)points,which were higher than(55.33±8.90)and(29.55±10.13)points in the control group(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Apatinib mesylate combined with Huoxue Lishui prescript is effective in the treatment of malignant ascites,and is a safe and effective regimen with few adverse reactions and good acceptance by patients.
作者
殷丽琴
黄帅
YIN Li-qin;HUANG Shuai(Department of Oncology,Kunshan First People's Hospital,Kunshan 323999,China)
出处
《中国实用医药》
2024年第13期134-137,共4页
China Practical Medicine
作者简介
通讯作者:黄帅。
